Skip to content
MARKETS / NASDAQ / PRPO
NASDAQ · LABORATORY ANALYTICAL INSTRUMENTS · SMALL CAP

Precipio, Inc. PRPO

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$24.0M
▲ 29.5% YoY
$-363,000
$359,000
▲ 66.2% YoY
In brief

What this company does

Our pathology services division provides specialized cancer diagnostic testing services to physicians, hospitals, and laboratories. This division generates revenue and supports the development of our expertise in oncology diagnostics. These products allow the Company to expand its reach by enabling other laboratories to benefit from the diagnostic products developed by the Company while building scalable diagnostic solutions. As of March 9, 2026, Precipio employed sixty-one (61) employees on a full-time basis and ten (10) employees as part-time. Precipio, Inc. was incorporated in Delaware on March 6, 1997. Our principal office is located at 4 Science Park, New Haven, Connecticut 06511.

Written from the business description in Precipio, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 30 March 2026. Every sentence was checked against that document before publication.

Growth
USD 24.0M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 24.0 · Net income -0.4
20M-20M200920112013201520172019202120232025
Compound annual growth
+36.7%
+31.6%
+28.7%
+1.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +31.6% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−2 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -5.0% · Net -1.5%
-500%-1000%-1500%200920112013201520172019202120232025
ROE
FY2024 · ROE -29.7%
-500%-1000%200920112013201520172019202120232025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 0.4
-5M-10M200920112013201520172019202120232025

Total assetsUSD 21.3M
CashUSD 2.7M
Gross debtUSD 77,000.00
Net debtUSD -2.6M
Current ratio1.61×

Not available: we don't have the shareholders' equity figure for this period.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.0−0.0−0.00.00.00.00.0−0.00.00.00.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0
EPS, diluted $−0.23−2.93−4.51−10.73−0.40−0.85−2.33−13.82−7.16−9.44−2.78−2.01−2.30−1.55−2.62−0.06−0.04
Dividend / sh $·················
Payout %·················
ROE %·−29.7−38.1−59.6−44.0−77.5−137.0−163.9−630.4·−1479.1−154.9−100.8−53.2−100.1−31.1−16.5
Shares out B0.000.000.000.000.020.020.010.000.010.000.010.010.010.010.050.05·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 82 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 13 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityLaboratory Analytical Instruments
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image